Trial reportClinical cancer research : an official journal of the American Association for Cancer Research2011
Targeting superficial or nodular Basal cell carcinoma with topically formulated small molecule inhibitor of smoothened.
Trial report in Clinical cancer research : an official journal of the American Association for Cancer Research, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 67 citations in OpenAlex.
- Tazarotene: randomized, double-blind, vehicle-controlled, and open-label concurrent trials for basal cell carcinoma prevention and therapy in patients with basal cell nevus syndrome.Cancer prevention research (Philadelphia, Pa.) · 2014Trial
- Decoding GPCR signaling reprogramming in cancer: molecular mechanisms and therapeutic implications.Molecular medicine (Cambridge, Mass.) · 2026Review
- Ablative fractional laser treatment reduces hedgehog pathway gene expression in murine basal cell carcinomas.Lasers in medical science · 2024Article
- Non-Surgical Therapeutic Strategies for Non-Melanoma Skin Cancers.Current treatment options in oncology · 2023Review
- Topical Delivery of Hedgehog Inhibitors: Current Status and Perspectives.International journal of molecular sciences · 2022Review
- Review
- The PROTAC selectively degrading Bcl-xTheranostics · 2022Article
- Anti-PD-1 Therapy with Adjuvant Ablative Fractional Laser Improves Anti-Tumor Response in Basal Cell Carcinomas.Cancers · 2021Article
- Potential Utility of Synthetic D-Lactate Polymers in Skin Cancer.JID innovations : skin science from molecules to population health · 2021Article
- Human skin models: From healthy to disease-mimetic systems; characteristics and applications.British journal of pharmacology · 2020Review
- The Role of Smoothened in Cancer.International journal of molecular sciences · 2020Review
- The Role of Dermal Fibroblasts in Nevoid Basal Cell Carcinoma Syndrome Patients: An Overview.International journal of molecular sciences · 2020Review
- Reproducibility of academic preclinical translational research: lessons from the development of Hedgehog pathway inhibitors to treat cancer.Open biology · 2018Review
- [What is new in basal cell carcinoma?]Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete · 2016Review
- Pharmacological evaluation of a series of smoothened antagonists in signaling pathways and after topical application in a depilated mouse model.Pharmacology research & perspectives · 2016Article
- Targeting the Sonic Hedgehog Signaling Pathway: Review of Smoothened and GLI Inhibitors.Cancers · 2016Review
- Skin models for the testing of transdermal drugs.Clinical pharmacology : advances and applications · 2016Review
- Article
- Sonidegib, a novel smoothened inhibitor for the treatment of advanced basal cell carcinoma.OncoTargets and therapy · 2016Review
- Everything Is Connected.The Journal of investigative dermatology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
purposeInappropriate activation of the Hedgehog (Hh) signaling pathway in skin is critical for the development of basal cell carcinomas (BCC). We have investigated the anti-BCC efficacy of topically-applied CUR61414, an inhibitor of the Hh signal transduction molecule Smoothened. EXPERIMENTAL
designIn preclinical studies, we used a depilatory model to evaluate the ability of topical formulations of CUR61414 to repress Hh responsive cells found at the base of hair follicles in normal skin. We also tested the in vivo effects of topical CUR61414 on murine BCCs developed in Ptch1 (+/-) K14-CreER2 p53 fl/fl mice. In a phase I clinical study, we evaluated the safety, tolerability, and efficacy of a multidose regimen of CUR61414 (0.09%, 0.35%, 1.1%, and 3.1%) applied topically to human superficial or nodular BCCs for up to 28 days.
resultsIn mice, topical CUR61414 significantly inhibited skin Hh signaling, blocked the induction of hair follicle anagen, and shrank existing BCCs. However, we observed no clinical activity of this formulation in human superficial or nodular BCCs in a phase I clinical study.
conclusionsOur data highlight some of the challenges of translating preclinical experience into successful human results for a topical anticancer agent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.